These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 31462270)

  • 1. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
    Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
    J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
    Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
    Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
    Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
    Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples.
    Kotsakis A; Harasymczuk M; Schilling B; Georgoulias V; Argiris A; Whiteside TL
    J Immunol Methods; 2012 Jul; 381(1-2):14-22. PubMed ID: 22522114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival.
    Fallah J; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Dann P; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan T; Garcia JA; Rini B; Ornstein MC; Grivas P
    Clin Genitourin Cancer; 2020 Dec; 18(6):500-508. PubMed ID: 32340875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
    Sheng IY; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan TD; Rini BI; Garcia JA; Grivas P; Ornstein MC
    Target Oncol; 2020 Apr; 15(2):211-220. PubMed ID: 32207064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD14
    Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
    Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells increase and inhibit donor-reactive T cell responses to graft intestinal epithelium in intestinal transplant patients.
    Okano S; Abu-Elmagd K; Kish DD; Keslar K; Baldwin WM; Fairchild RL; Fujiki M; Khanna A; Osman M; Costa G; Fung J; Miller C; Kayashima H; Hashimoto K
    Am J Transplant; 2018 Oct; 18(10):2544-2558. PubMed ID: 29509288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
    Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
    Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.
    Lechner MG; Megiel C; Russell SM; Bingham B; Arger N; Woo T; Epstein AL
    J Transl Med; 2011 Jun; 9():90. PubMed ID: 21658270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
    Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
    Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoplasmic reticulum stress induced LOX-1
    Nan J; Xing YF; Hu B; Tang JX; Dong HM; He YM; Ruan DY; Ye QJ; Cai JR; Ma XK; Chen J; Cai XR; Lin ZX; Wu XY; Li X
    Immunology; 2018 May; 154(1):144-155. PubMed ID: 29211299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.
    Cole KE; Ly QP; Hollingsworth MA; Cox JL; Padussis JC; Foster JM; Vargas LM; Talmadge JE
    Cell Immunol; 2021 May; 363():104317. PubMed ID: 33714729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
    Wang D; An G; Xie S; Yao Y; Feng G
    Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.